Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation

  • Bueno-Costa, Alberto
  • Piñeyro, David
  • Soler, Marta
  • Javierre, Biola M.
  • Raurell Vila, Helena
  • Subirana-Granés, Marc
  • Pasquali, Lorenzo
  • Martinez-Climent, Jose A.
  • Esteller, Manel
This work was supported by the Health Department PERIS-project no. SLT/002/16/00374 and AGAUR-projects no. 2017SGR1080, 2014SGR633, 2017SGR1033, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project no. DTS16/00153, and CIBERONC CB16/12/00312 and CB16/12/00489; and Ministerio de Economía y Competitividad (MINECO) project nos. SAF2014-55000-R, BFU2014-57466-P, SAF2017-89673-R, SAF2017-86242-R, and SAF2015-70270-REDT cofinanced by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF; the Cellex Foundation; and “la Caixa” Bank Foundation (LCF/PR/GN18/51140001). We thank Dr Thomas Graf for providing the transdifferentiation model.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the endoplasmic reticulum-associated degradation inhibitor SVIP induces cancer cell metabolic reprogramming

  • Llinàs Arias, Pere
  • Moutinho, Catia
  • Esteller, Manel
The endoplasmic reticulum (ER) of cancer cells needs to adapt to the enhanced proteotoxic stress associated with the accumulation of unfolded, misfolded and transformation-associated proteins. One way by which tumors thrive in the context of ER stress is by promoting ER-Associated Degradation (ERAD), although the mechanisms are poorly understood. Here, we show that the Small p97/VCP Interacting Protein (SVIP), an endogenous inhibitor of ERAD, undergoes DNA hypermethylation-associated silencing in tumorigenesis to achieve this goal. SVIP exhibits tumor suppressor features and its recovery is associated with increased ER stress and growth inhibition. Proteomic and metabolomic analyses show that cancer cells with epigenetic loss of SVIP are depleted in mitochondrial enzymes and oxidative respiration activity. This phenotype is reverted upon SVIP restoration. The dependence of SVIP hypermethylated cancer cells on aerobic glycolysis and glucose was also associated with sensitivity to an inhibitor of the glucose transporter GLUT1. This could be relevant to the management of tumors carrying SVIP epigenetic loss, because these occur in high-risk patients who manifest poor clinical outcomes. Overall, our study provides insights into how epigenetics helps deal with ER stress and how SVIP epigenetic loss in cancer may be amenable to therapies that target glucose transporters., This work was supported by the Health Department PERIS project number SLT/002/16/00374 and AGAUR project numbers 2017SGR1080, 2014SGR633, 2017SGR1033, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project number DTS16/00153 and Ministerio de Economía y Competitividad (MINECO) project numbers SAF2014-55000-R, BFU2014-57466-P, SAF2017-89673-R, and SAF2015-70270-REDT co-financed by the European Development Regional Fund, A way to achieve Europe ERDF; the Cellex Foundation; and “la Caixa” Bank Foundation (LCF/PR/PR15/11100003). MC acknowledges the prize “ICREA Academia” for excellence in research, funded by ICREA foundation. We thank the Scientific and Technological Centre (CCiTUB) of the University of Barcelona for technical support with cell cytometry and sorting. We also thank the Regenerative Medicine Center (CMRB) Electron Microscopy and Histology facility.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A DNA methylation map of human cancer at single base-pair resolution

  • Vidal Ocabo, Enrique
  • Sayols, Sergi
  • Moran, Sebastian
  • Guillaumet-Adkins, Amy
  • Schroeder, Michael Philipp, 1986-
  • Royo, Romina
  • Orozco, Modesto
  • Gut, Marta
  • Gut, Ivo Glynne
  • López Bigas, Núria
  • Heyn, Holger
  • Esteller, Manel
Although single base-pair resolution DNA methylation landscapes for embryonic and different somatic cell types provided important insights into epigenetic dynamics and cell-type specificity, such comprehensive profiling is incomplete across human cancer types. This prompted us to perform genome-wide DNA methylation profiling of 22 samples derived from normal tissues and associated neoplasms, including primary tumors and cancer cell lines. Unlike their invariant normal counterparts, cancer samples exhibited highly variable CpG methylation levels in a large proportion of the genome, involving progressive changes during tumor evolution. The whole-genome sequencing results from selected samples were replicated in a large cohort of 1112 primary tumors of various cancer types using genome-scale DNA methylation analysis. Specifically, we determined DNA hypermethylation of promoters and enhancers regulating tumor-suppressor genes, with potential cancer-driving effects. DNA hypermethylation events showed evidence of positive selection, mutual exclusivity and tissue specificity, suggesting their active participation in neoplastic transformation. Our data highlight the extensive changes in DNA methylation that occur in cancer onset, progression and dissemination., This work was supported by Institute of Health Carlos III ISCIII Project no. PI11/00321, Spanish Cancer Research Network (RTICC) no. RD12/0036/0039; European Development Regional Fund, ‘A way to achieve Europe’ ERDF (SAF2014-55000-R), Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation; AGAUR 2014SGR633 grant; Health and Science Departments of the Catalan government (Generalitat de Catalunya) and European Community's Seventh Framework Program (FP7/2007-2013), grant HEALTH-F5-2011-282510 – BLUEPRINT. HH is a Miguel Servet (CP14/00229) ISCII researcher.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis

  • Anadón, C.
  • Guil, S.
  • Simó-Riudalbas, L.
  • Moutinho, C.
  • Setien, F.
  • Martínez-Cardús, A.
  • Moran, S.
  • Villanueva, A.
  • Calaf, M.
  • Vidal, August
  • Lazo, Pedro A.
  • Zondervan, I.
  • Savola, S.
  • Kohno, T.
  • Yokota, J.
  • Pouplana, L. R. de
  • Esteller, M.
The introduction of new therapies against particular genetic mutations in non-small-cell lung cancer is a promising avenue for improving patient survival, but the target population is small. There is a need to discover new potential actionable genetic lesions, to which end, non-conventional cancer pathways, such as RNA editing, are worth exploring. Herein we show that the adenosine-toinosine editing enzyme ADAR1 undergoes gene amplification in non-small cancer cell lines and primary tumors in association with higher levels of the corresponding mRNA and protein. From a growth and invasion standpoint, the depletion of ADAR1 expression in amplified cells reduces their tumorigenic potential in cell culture and mouse models, whereas its overexpression has the opposite effects. From a functional perspective, ADAR1 overexpression enhances the editing frequencies of target transcripts such as NEIL1 and miR-381. In the clinical setting, patients with early-stage lung cancer, but harboring ADAR1 gene amplification, have poor outcomes. Overall, our results indicate a role for ADAR1 as a lung cancer oncogene undergoing gene amplification-associated activation that affects downstream RNA editing patterns and patient prognosis., This work was supported by the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 268626—EPINORC project, the Grant agreement number HEALTH-F2-2010-258677—CURELUNG project, the Spanish Ministry of Economy and Competitiveness (MINECO Projects no. SAF2011-22803, PI13-01339 and SAF2014-55000- R), the Institute of Health Carlos III (ISCIII)—PI10/02992, Ministerio de Educación, Ciencia e Innovación Grant SAF2010-14935, the Cellex Foundation, the National Cancer Center Research and Development Fund (NCC Biobank: 23 A-1) and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR—project no. 2009SGR1315 and 2014SGR633., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Castro de Moura, Manuel
  • Martínez‑Cardús, Anna
  • Llinàs‑Arias, Pere
  • Soler, Marta
  • Nachmani, Daphna
  • Pelletier, Joffrey
  • Schumann, Ulrike
  • Calleja‑Cervantes, Maria E.
  • Morán, Sebastián
  • Guil, Sonia
  • Bueno-Costa, Alberto
  • Piñeyro, David
  • Perez‑Salvia, Montserrat
  • Rosselló‑Tortella, Margalida
  • Piqué, Laia
  • Bech‑Serra, Joan J.
  • Torre, Carolina de la
  • Vidal, August
  • Martínez‑Iniesta, María
  • Martín‑Tejera, Juan F.
  • Villanueva, Alberto
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.
  • Morales La Madrid, Andres
  • Carcaboso, Ángel M.
  • Santa‑Maria, Vicente
  • Mora, Jaume
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Aldecoa, Iban
  • Pedrosa, Leire
  • Graus, Francesc
  • Vidal Sarró, Noemí
  • Martínez‑Soler, Fina
  • Tortosa, Avelina
  • Carrato, Cristina
  • Balañá, Carme
  • Boudreau, Matthew W.
  • Hergenrother, Paul J.
  • Kötter, Peter
  • Entian, Karl‑Dieter
  • Hench, Jürgen
  • Frank, Stephan
  • Mansouri, Sheila
  • Zadeh, Gelareh
  • Dans, Pablo D.
  • Orozco, Modesto
  • Thomas, George
  • Blanco, Sandra
  • Seoane, Joan
  • Preiss, Thomas
  • Pandolfi, Pier Paolo
  • Esteller, Manel
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease., This work was supported by a European Research Council (ERC) Advanced Grant under the European Community’s Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement No. 268626—EPINORC project (to M. Esteller), the Ministerio de Economía y Competitividad (MINECO) under Grant No. SAF2014-55000-R (to M. Esteller) and the Instituto de Salud Carlos III (ISCIII), under the FIS PI16/01278 Project (to J. Seoane), the Integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE) (to M. Esteller), CIBER 2016 CB16/12/00312 (CIBERONC) (to M. Esteller), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, the AGAUR—Catalan Government (Project No. 2009SGR1315 and 2014SGR633) (to M. Esteller), the Cellex Foundation (to M. Esteller), Obra Social “La Caixa” (to M. Esteller), the CERCA Program and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) (to M. Esteller) and a grant from the National Health and Medical Research Council of Australia (APP1061551, to TP). M.W. Boudreau is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM070421).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Germline variation in O6-methylguanine-DNA methyltransferase (MGMT) as cause of hereditary colorectal cancer

  • Belhadj, Sami
  • Moutinho, Catia
  • Mur, Pilar
  • Setien, Fernando
  • Llinàs‑Arias, Pere
  • Pérez-Salvia, Montserrat
  • Pons, Tirso
  • Pineda, Marta
  • Brunet, Joan
  • Navarro, Matilde
  • Capellá, Gabriel
  • Esteller, Manel
  • Valle, Laura
© 2019 The Authors., Somatic epigenetic inactivation of the DNA repair protein O6-methylguanine DNA methyltransferase (MGMT) is frequent in colorectal cancer (CRC); however, its involvement in CRC predisposition remains unexplored. We assessed the role and relevance of MGMT germline mutations and epimutations in familial and early-onset CRC. Mutation and promoter methylation screenings were performed in 473 familial and/or early-onset mismatch repair-proficient nonpolyposis CRC cases. No constitutional MGMT inactivation by promoter methylation was observed. Of six rare heterozygous germline variants identified, c.346C > T (p.H116Y) and c.476G > A (p.R159Q), detected in three and one families respectively, affected highly conserved residues and showed segregation with cancer in available family members. In vitro, neither p.H116Y nor p.R159Q caused statistically significant reduction of MGMT repair activity. No evidence of somatic second hits was found in the studied tumors. Case-control data showed over-representation of c.346C > T (p.H116Y) in familial CRC compared to controls, but no overall association of MGMT mutations with CRC predisposition. In conclusion, germline mutations and constitutional epimutations in MGMT are not major players in hereditary CRC. Nevertheless, the over-representation of c.346C > T (p.H116Y) in our familial CRC cohort warrants further research., This work was funded by the Spanish Ministry of Science, Innovation and Universities, co-funded by FEDER funds -a way to build Europe- [SAF2016-80888-R (LV), SAF2014-55000-R (ME), SAF2015-68016-R (GC/MP), Juan de la Cierva and Sara Borrell postdoctoral contracts (PM)]; Instituto de Salud Carlos III [DTS16/00153 (ME) and CIBERONC CB16/12/00234]; the Government of Catalonia [Pla Estratègic de Recerca i Innovació en Salut SLT002/16/0037, 2017SGR1282, 2017SGR1080, 2014SGR633 and 2009SGR1315]; and Fundación Olga Torres. We thank the CERCA/Generalitat de Catalunya Program for institutional support. This study has been enabled by COST Action CA17118.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Look-alike humans identified by facial recognition algorithms show genetic similarities

  • Joshi, Ricky S.
  • Rigau, Maria
  • García-Prieto, Carlos A.
  • Castro de Moura, Manuel
  • Piñeyro, David
  • Moran, Sebastian
  • Dávalos, Verónica
  • Carrión, Pablo
  • Ferrando-Bernal, Manuel
  • Olalde, Iñigo
  • Lalueza-Fox, Carles
  • Navarro, Arcadi
  • Fernández-Tena, Carles
  • Aspandi, Decky
  • Sukno, Federico M.
  • Binefa, Xavier
  • Valencia, Alfonso
  • Esteller, Manel
The human face is one of the most visible features of our unique identity as individuals. Interestingly, monozygotic twins share almost identical facial traits and the same DNA sequence but could exhibit differences in other biometrical parameters. The expansion of the world wide web and the possibility to exchange pictures of humans across the planet has increased the number of people identified online as virtual twins or doubles that are not family related. Herein, we have characterized in detail a set of “look-alike” humans, defined by facial recognition algorithms, for their multiomics landscape. We report that these individuals share similar genotypes and differ in their DNA methylation and microbiome landscape. These results not only provide insights about the genetics that determine our face but also might have implications for the establishment of other human anthropometric properties and even personality characteristics., This work was funded by the governments of Catalonia (2017SGR1080) and Spain (RTI2018-094049-B-I00, SAF2014-55000, and TIN2017-90124-P) and the Cellex Foundation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2

  • Martínez De Paz, A.
  • Khajavi, L.
  • Martin, H.
  • Claveria-Gimeno, R.
  • Tom Dieck, S.
  • Cheema, M.S.
  • Sanchez-Mut, J.V.
  • Moksa, M.M.
  • Carles, A.
  • Brodie, N.I.
  • Sheikh, T.I.
  • Freeman, M.E.
  • Petrotchenko, E.V.
  • Borchers, C.H.
  • Schuman, E.M.
  • Zytnicki, M.
  • Velazquez-Campoy, A.
  • Abian, O.
  • Hirst, M.
  • Esteller, M.
  • Vincent, J.B.
  • Malnou, C.E.
  • Ausió, J.
Background: MeCP2- A chromatin-binding protein associated with Rett syndrome-has two main isoforms, MeCP2-E1 and MeCP2-E2, differing in a few N-terminal amino acid residues. Previous studies have shown brain region-specific expression of these isoforms which, in addition to their different cellular localization and differential expression during brain development, suggest that they may also have non-overlapping molecular mechanisms. However, differential functions of MeCP2-E1 and E2 remain largely unexplored. Results: Here, we show that the N-terminal domains (NTD) of MeCP2-E1 and E2 modulate the ability of the methyl-binding domain (MBD) to interact with DNA as well as influencing the turn-over rates, binding dynamics, response to neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both isoforms exhibit unique interacting protein partners. Moreover, genome-wide analysis using ChIP-seq provide evidence for a shared as well as a specific regulation of different sets of genes. Conclusions: Our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular processes involving non-overlapping functions of MECP2 isoforms. For instance, MeCP2-E1 mutations might impact stimuli-dependent chromatin regulation, while MeCP2-E2 mutations could result in aberrant ribosomal expression. Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its two isoforms.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A DNA methylation map of human cancer at single base-pair resolution

  • Vidal Ocabo, Enrique
  • Sayols, Sergi
  • Moran, Sebastian
  • Guillaumet-Adkins, Amy
  • Schroeder, Michael Philipp, 1986-
  • Royo, Romina
  • Orozco, Modesto
  • Gut, Marta
  • Gut, Ivo Glynne
  • López Bigas, Núria
  • Heyn, Holger
  • Esteller, Manel
Although single base-pair resolution DNA methylation landscapes for embryonic and different somatic cell types provided important insights into epigenetic dynamics and cell-type specificity, such comprehensive profiling is incomplete across human cancer types. This prompted us to perform genome-wide DNA methylation profiling of 22 samples derived from normal tissues and associated neoplasms, including primary tumors and cancer cell lines. Unlike their invariant normal counterparts, cancer samples exhibited highly variable CpG methylation levels in a large proportion of the genome, involving progressive changes during tumor evolution. The whole-genome sequencing results from selected samples were replicated in a large cohort of 1112 primary tumors of various cancer types using genome-scale DNA methylation analysis. Specifically, we determined DNA hypermethylation of promoters and enhancers regulating tumor-suppressor genes, with potential cancer-driving effects. DNA hypermethylation events showed evidence of positive selection, mutual exclusivity and tissue specificity, suggesting their active participation in neoplastic transformation. Our data highlight the extensive changes in DNA methylation that occur in cancer onset, progression and dissemination., This work was supported by Institute of Health Carlos III ISCIII Project no. PI11/00321, Spanish Cancer Research Network (RTICC) no. RD12/0036/0039; European Development Regional Fund, ‘A way to achieve Europe’ ERDF (SAF2014-55000-R), Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation; AGAUR 2014SGR633 grant; Health and Science Departments of the Catalan government (Generalitat de Catalunya) and European Community's Seventh Framework Program (FP7/2007-2013), grant HEALTH-F5-2011-282510 – BLUEPRINT. HH is a Miguel Servet (CP14/00229) ISCII researcher.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation

  • Bueno-Costa, Alberto
  • Piñeyro, David
  • Soler, Marta
  • Javierre, Biola M.
  • Raurell Vila, Helena
  • Subirana-Granés, Marc
  • Pasquali, Lorenzo
  • Martinez-Climent, Jose A.
  • Esteller, Manel
This work was supported by the Health Department PERIS-project no. SLT/002/16/00374 and AGAUR-projects no. 2017SGR1080, 2014SGR633, 2017SGR1033, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project no. DTS16/00153, and CIBERONC CB16/12/00312 and CB16/12/00489; and Ministerio de Economía y Competitividad (MINECO) project nos. SAF2014-55000-R, BFU2014-57466-P, SAF2017-89673-R, SAF2017-86242-R, and SAF2015-70270-REDT cofinanced by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF; the Cellex Foundation; and “la Caixa” Bank Foundation (LCF/PR/GN18/51140001). We thank Dr Thomas Graf for providing the transdifferentiation model.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Castro de Moura, Manuel
  • Martínez‑Cardús, Anna
  • Llinàs‑Arias, Pere
  • Soler, Marta
  • Arias Piñeiro, Alexandra
  • Cuartas Maza, Ma Isabel
  • Seoane Suarez, Joan
Resultado clínico; Epitranscriptómica; Glioma, Clinical outcome; Epitranscriptomics; Glioma, Resultat clínic; Epitranscriptòmica; Glioma, Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease., This work was supported by a European Research Council (ERC) Advanced Grant under the European Community’s Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement No. 268626—EPINORC project (to M. Esteller), the Ministerio de Economía y Competitividad (MINECO) under Grant No. SAF2014-55000-R (to M. Esteller) and the Instituto de Salud Carlos III (ISCIII), under the FIS PI16/01278 Project (to J. Seoane), the Integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE) (to M. Esteller), CIBER 2016 CB16/12/00312 (CIBERONC) (to M. Esteller), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, the AGAUR—Catalan Government (Project No. 2009SGR1315 and 2014SGR633) (to M. Esteller), the Cellex Foundation (to M. Esteller), Obra Social “La Caixa” (to M. Esteller), the CERCA Program and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) (to M. Esteller) and a grant from the National Health and Medical Research Council of Australia (APP1061551, to TP). M.W. Boudreau is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM070421).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the endoplasmic reticulum-associated degradation inhibitor SVIP induces cancer cell metabolic reprogramming

  • Llinàs Arias, Pere
  • Moutinho, Catia
  • Esteller, Manel
The endoplasmic reticulum (ER) of cancer cells needs to adapt to the enhanced proteotoxic stress associated with the accumulation of unfolded, misfolded and transformation-associated proteins. One way by which tumors thrive in the context of ER stress is by promoting ER-Associated Degradation (ERAD), although the mechanisms are poorly understood. Here, we show that the Small p97/VCP Interacting Protein (SVIP), an endogenous inhibitor of ERAD, undergoes DNA hypermethylation-associated silencing in tumorigenesis to achieve this goal. SVIP exhibits tumor suppressor features and its recovery is associated with increased ER stress and growth inhibition. Proteomic and metabolomic analyses show that cancer cells with epigenetic loss of SVIP are depleted in mitochondrial enzymes and oxidative respiration activity. This phenotype is reverted upon SVIP restoration. The dependence of SVIP hypermethylated cancer cells on aerobic glycolysis and glucose was also associated with sensitivity to an inhibitor of the glucose transporter GLUT1. This could be relevant to the management of tumors carrying SVIP epigenetic loss, because these occur in high-risk patients who manifest poor clinical outcomes. Overall, our study provides insights into how epigenetics helps deal with ER stress and how SVIP epigenetic loss in cancer may be amenable to therapies that target glucose transporters., This work was supported by the Health Department PERIS project number SLT/002/16/00374 and AGAUR project numbers 2017SGR1080, 2014SGR633, 2017SGR1033, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project number DTS16/00153 and Ministerio de Economía y Competitividad (MINECO) project numbers SAF2014-55000-R, BFU2014-57466-P, SAF2017-89673-R, and SAF2015-70270-REDT co-financed by the European Development Regional Fund, A way to achieve Europe ERDF; the Cellex Foundation; and “la Caixa” Bank Foundation (LCF/PR/PR15/11100003). MC acknowledges the prize “ICREA Academia” for excellence in research, funded by ICREA foundation. We thank the Scientific and Technological Centre (CCiTUB) of the University of Barcelona for technical support with cell cytometry and sorting. We also thank the Regenerative Medicine Center (CMRB) Electron Microscopy and Histology facility.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia

  • Anadón, C.
  • van Tetering, G.
  • Ferreira, H. J.
  • Moutinho, Catia|||0000-0003-3885-0847
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Soler, Marta|||0000-0002-6656-957X
  • Heyn, Holger|||0000-0002-3276-1889
  • Moran, S.|||0000-0003-4192-8983
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Setien, F.
  • Vidal, A.
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Guil, Sonia|||0000-0002-2257-3331
  • Esteller, M.|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime|||0000-0003-1013-4128
  • Ortiz-Barahona, V.
  • de Moura, M. C.
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Soler, Marta|||0000-0002-6656-957X
  • Nachmani, D.
  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Schumann, U.
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Moran, S.|||0000-0003-4192-8983
  • Guil, Sonia|||0000-0002-2257-3331
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Piñeyro, David|||0000-0001-5633-3339
  • Perez-Salvia, Montserrat
  • Rosselló-Tortella, M.
  • Piqué, Laia
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Vidal, August|||0000-0001-5727-2099
  • Martínez-Iniesta, M.
  • Martín-Tejera, J. F.
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.|||0000-0002-8271-612X
  • La Madrid, A. M.
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Santa-Maria, V.
  • Mora, J.
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fraga, M. F.
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Vidal, Noemí|||0000-0002-2852-6667
  • Martinez, Fina|||0000-0002-0940-1025
  • Tortosa, Avelina|||0000-0002-9080-2976
  • Carrato, Cristina|||0000-0002-1953-8287
  • Balañá, Carmen|||0000-0003-0771-0390
  • Boudreau, M. W.
  • Hergenrother, P. J.
  • Kötter, P.
  • Entian, K. D.
  • Hench, Jürgen
  • Frank, Stephan|||0000-0001-6165-0187
  • Mansouri, S.
  • Zadeh, G.
  • Dans, P. D.
  • Orozco López, Modesto|||0000-0002-8608-3278
  • Thomas, Gareth J.
  • Blanco, Sandra
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Preiss, T.
  • Pandolfi, P. P.
  • Esteller, M.|||0000-0003-4490-6093
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer

  • Piqué, Laia
  • Martinez de Paz, A.
  • Piñeyro, David|||0000-0001-5633-3339
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Setien, F.
  • Gómez-Miragaya, Jorge|||0000-0003-1801-4681
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Sigurdsson, S.|||0000-0002-5284-0058
  • Jonasson, J. G.
  • Villanueva, Alberto|||0000-0001-5164-0006
  • Vidal, A.
  • Davalos, Veronica|||0000-0003-4077-5137
  • Esteller, M.|||0000-0003-4490-6093
Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma, implications for biomarker-driven clinical trials

  • Montal, Robert
  • Andreu-Oller, Carmen|||0000-0001-7405-9134
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Esteban-Fabró, Roger
  • Moran, S.|||0000-0003-4192-8983
  • Montironi, Carla|||0000-0002-1453-2193
  • Moeini, Agrin
  • Pinyol, Roser|||0000-0002-0288-6314
  • Peix, Judit
  • Cabellos, Laia
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Sia, Daniela|||0000-0002-9000-611X
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
  • Esteller, M.|||0000-0003-4490-6093
  • Llovet, Josep M.|||0000-0003-0547-2667
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The transcribed pseudogene RPSAP52 enhances the oncofetal HMGA2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition

  • Oliveira-Mateos, Cristina|||0000-0003-2574-7816
  • Sánchez Castillo, Anaís|||0000-0003-4024-976X
  • Soler, Marta|||0000-0002-6656-957X
  • Obiols-Guardia, Aida|||0000-0002-2548-8597
  • Piñeyro, David|||0000-0001-5633-3339
  • Boque-Sastre, Raquel|||0000-0002-0214-8848
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Rubio Lopez, Maria Teresa|||0000-0003-0843-528X
  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Martínez-Iniesta, Maria|||0000-0001-6252-6671
  • Herrero-Martín, David|||0000-0001-6548-6812
  • Tirado, Oscar M.|||0000-0002-4666-2822
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Esteller, M.|||0000-0003-4490-6093
  • Farré, Lourdes|||0000-0002-3168-1940
  • Guil, Sonia|||0000-0002-2257-3331
One largely unknown question in cell biology is the discrimination between inconsequential and functional transcriptional events with relevant regulatory functions. Here, we find that the oncofetal HMGA2 gene is aberrantly reexpressed in many tumor types together with its antisense transcribed pseudogene RPSAP52. RPSAP52 is abundantly present in the cytoplasm, where it interacts with the RNA binding protein IGF2BP2/IMP2, facilitating its binding to mRNA targets, promoting their translation by mediating their recruitment on polysomes and enhancing proliferative and self-renewal pathways. Notably, downregulation of RPSAP52 impairs the balance between the oncogene LIN28B and the tumor suppressor let-7 family of miRNAs, inhibits cellular proliferation and migration in vitro and slows down tumor growth in vivo. In addition, high levels of RPSAP52 in patient samples associate with a worse prognosis in sarcomas. Overall, we reveal the roles of a transcribed pseudogene that may display properties of an oncofetal master regulator in human cancers.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Castro de Moura, Manuel
  • Martínez‑Cardús, Anna
  • Llinàs‑Arias, Pere
  • Soler, Marta
  • Arias Piñeiro, Alexandra
  • Cuartas Maza, Ma Isabel
  • Seoane Suarez, Joan
Resultado clínico; Epitranscriptómica; Glioma, Clinical outcome; Epitranscriptomics; Glioma, Resultat clínic; Epitranscriptòmica; Glioma, Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease., This work was supported by a European Research Council (ERC) Advanced Grant under the European Community’s Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement No. 268626—EPINORC project (to M. Esteller), the Ministerio de Economía y Competitividad (MINECO) under Grant No. SAF2014-55000-R (to M. Esteller) and the Instituto de Salud Carlos III (ISCIII), under the FIS PI16/01278 Project (to J. Seoane), the Integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE) (to M. Esteller), CIBER 2016 CB16/12/00312 (CIBERONC) (to M. Esteller), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, the AGAUR—Catalan Government (Project No. 2009SGR1315 and 2014SGR633) (to M. Esteller), the Cellex Foundation (to M. Esteller), Obra Social “La Caixa” (to M. Esteller), the CERCA Program and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) (to M. Esteller) and a grant from the National Health and Medical Research Council of Australia (APP1061551, to TP). M.W. Boudreau is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM070421).